Form 4: Alzamend Neuro Director Ault Reports Stock Transactions

Milton C. Ault III, a director and 10% owner of Alzamend Neuro, Inc., reported recent acquisitions and disposals of common stock, along with holdings of derivative securities.

Summary

• Milton C. Ault III, a Director and 10% Owner of Alzamend Neuro, Inc. (ALZN), reported changes in his beneficial ownership.
• On September 17, 2025, 100,000 shares of common stock were acquired at $2.32 per share through the conversion of Series B convertible preferred stock.
• On September 17, 2025, 2,121 shares of common stock were disposed of at an average price of $2.4535 per share.
• On September 18, 2025, an additional 20,870 shares of common stock were disposed of at an average price of $2.4673 per share.
• All reported transactions and holdings are indirect, primarily through Ault Lending, LLC, Ault Life Sciences, Inc., and Ault Life Sciences Fund, LLC, entities where Mr. Ault has voting and investment power.
• Following these transactions, Mr. Ault's indirect beneficial ownership through Ault Lending, LLC, stands at 85,269 shares of common stock, 1,303.2447 shares of Series B Convertible Preferred Stock, and 23,334 Common Stock Purchase Warrants.

Sentiment

Score: 5

Explanation: The filing is a factual report of insider transactions, which are inherently neutral in tone. While sales by a director can sometimes be perceived negatively, the filing itself does not convey a positive or negative sentiment.

Positives

• The conversion of Series B convertible preferred stock into common stock occurred at a price of $2.32 per share, which is lower than the subsequent sale prices, indicating a profitable conversion for the reporting person.

Negatives

• A director and 10% owner disposed of 2,121 shares of common stock at $2.4535 and 20,870 shares at $2.4673, which could be perceived by the market as a reduction in insider exposure.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The reported transactions involve Milton C. Ault III, a Director and 10% Owner of Alzamend Neuro, Inc., making these related-party transactions.
• Mr. Ault's beneficial ownership is primarily indirect, held through entities he controls: Ault Lending, LLC (a wholly-owned subsidiary of Hyperscale Data, Inc., where Mr. Ault is Executive Chairman), Ault Life Sciences, Inc., and Ault Life Sciences Fund, LLC.

Stakeholder Impact

• Shareholders may view the sale of common stock by a director and 10% owner as a signal, potentially influencing market perception of the company's stock value.
• The conversion of preferred stock to common stock increases the number of common shares beneficially owned by the insider, while the subsequent sales reduce direct exposure.

Key Dates

Keywords

Alzamend Neuro, ALZN, Milton C. Ault III, Insider Trading, Beneficial Ownership, Form 4, Stock Transactions, Director, 10% Owner, Common Stock, Preferred Stock, Warrants